Non-Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma / chronic lymphocytic leukemia therapy market. Key therapies expected to fuel growth are the CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb), as well as the targeted agents Polivy (Roche), Monjuvi / Minjuvi (MorphoSys / Incyte), Tazverik (Epizyme), Brukinsa (BeiGene), and Zynlonta (ADC Therapeutics). In addition, combinations incorporating Imbruvica (Janssen / AbbVie), Calquence (AstraZeneca), and Venclexta / Venclyxto (AbbVie / Roche) will enter the CLL market, resulting in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of the bispecific antibodies glofitamab (Roche), mosunetuzumab (Roche), and epcoritamab (Genmab / AbbVie) and the noncovalent BTK inhibitor pirtobrutinib (Loxo Oncology / Eli Lilly) will further fragment the DLBCL, FL, and CLL / SLL patient settings, creating intense competition.

Questions Answered

  • What is the size of clinically and commercially relevant drug-treatable NHL / CLL populations, and how will drug-treatment rates change over the 2021-2031 forecast period, by geography?
  • What is the expected market impact of recent drug approvals and label expansions on the various NHL / CLL patient populations?
  • Which emerging therapies are the most promising in NHL / CLL, and what patient populations will they target? What will be their impact on the NHL / CLL market?
  • What factors are driving growth in the NHL / CLL market? Which drug class will dominate the treatment of NHL / CLL?

Content Highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of NHL by country; drug-treatable and drug-treated cases segmented by subtype (follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia / small lymphocytic leukemia) and line of therapy.

Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.

Emerging therapies: Phase I/II: 19 drugs; Phase III / PR: 11 drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast
    • Key findings
      • Key findings on non-Hodgkinu2019s lymphoma
    • Key updates
      • Q3 2022
        • July 2022
      • Q2 2022
        • June 2022
        • May 2022
        • May 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • November 2021
      • Q3 2021
        • August 2021
        • July 2021
    • Market outlook
      • Key findings
        • Market share of drug classes for non-Hodgkin's lymphoma: 2020
        • Market share of drug classes for non-Hodgkin's lymphoma: 2030
        • Positioning of key therapies in chronic lymphocytic leukemia / small lymphocytic lymphoma in the United States: 2020-2030
        • Positioning of key therapies in diffuse large B-cell lymphoma in the United States: 2020-2030
        • Positioning of key therapies in follicular lymphoma in the United States: 2020-2030
        • Positioning of key therapies in mantle cell lymphoma in the United States: 2020-2030
        • Non-Hodgkin's lymphoma SWOT analysis
        • Current therapies with sales potential in non-Hodgkin's lymphoma: population positioning
        • Emerging therapies with sales potential in non-Hodgkin's lymphoma: population positioning
      • Market drivers and constraints
        • What factors are driving the market for NHL?
        • What factors are constraining the market for NHL?
        • Drug-treatable population share and major-market sales share for CLL / SLL: 2020
        • Drug-treatable population share and major-market sales share for CLL / SLL: 2030
        • Drug-treatable population share and major-market sales share for DLBCL: 2020
        • Drug-treatable population share and major-market sales share for DLBCL: 2030
        • Drug-treatable population share and major-market sales share for FL: 2020
        • Drug-treatable population share and major-market sales share for FL: 2030
        • Drug-treatable population share and major-market sales share for MCL: 2020
        • Drug-treatable population share and major-market sales share for MCL: 2030
        • Major-market non-Hodgkin's lymphoma sales by subpopulation: 2020-2030
        • Key non-Hodgkin's lymphoma therapies with major-market sales exceeding $1.0 billion in 2030
      • Segment-specific trends
        • Patient-share dynamics of key drug classes in first-line CLL / SLL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in first-line CLL / SLL in the United States: 2020-2030
        • Sales of key therapies for first-line CLL / SLL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in second-line CLL / SLL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in third-line CLL / SLL in the United States: 2020-2030
        • Sales of key therapies for second-line CLL / SLL in the United States: 2020-2030
        • Sales of key therapies for third-line CLL / SLL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in first-line DLBCL in the United States: 2020-2030
        • Sales of key therapies for first-line DLBCL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in second-line DLBCL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in third-line DLBCL in the United States: 2020-2030
        • Sales of key therapies for second-line DLBCL in the United States: 2020-2030
        • Sales of key therapies for third-line DLBCL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in first-Line FL in the United States: 2020-2030
        • Sales of key therapies for first-line FL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in second-line FL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in third-line FL in the United States: 2020-2030
        • Sales of key therapies for second-line FL in the United States: 2020-2030
        • Sales of key therapies for third-line FL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in first-line MCL in the United States: 2020-2030
        • Sales of key therapies for first-line MCL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in second-Line MCL in the United States: 2020-2030
        • Patient-share dynamics of key therapies in third-line MCL in the United States: 2020-2030
        • Sales of key therapies for second-line MCL in the United States: 2020-2030
        • Sales of key therapies for third-line MCL in the United States: 2020-2030
    • Forecast
      • Market forecast assumptions
      • Market forecast dashboard
    • Etiology and pathophysiology
      • Disease overview
        • Disease pathophysiology
          • Select risk factors associated with non-Hodgkin's lymphoma
          • International prognostic index scoring for NHL patients of all ages
          • Revised international prognostic index score in patients treated with R-CHOP
          • Select biomarkers for non-Hodgkin's lymphoma subpopulations predicting clinical outcome
        • Staging and classification
          • Staging of non-Hodgkin's lymphoma
          • Revised Ann Arbor staging system for primary nodal lymphomas
          • The Binet staging system for CLL / SLL
          • The Rai staging system for CLL / SLL
          • Normal B-cell development and cellular origin of B-cell malignancies
        • Key pathways and drug targets
          • Key drug targets for non-Hodgkin's lymphoma
          • Select drug targets currently exploited or in development for non-Hodgkin's lymphoma and chronic lymphocytic leukemia
          • Immune checkpoint activation and pathways
      • Epidemiology
        • Key findings
          • Epidemiology populations
            • Disease definition
            • Methods
            • Sources used for diagnosed incidence of the various NHL subtypes
            • Number of diagnosed incident cases of NHL in the major pharmaceutical markets by subtype: 2020-2030
            • Disease definition
            • Methods
            • Sources used for molecular subtype of de novo DLBCL incident cases
            • Number of diagnosed incident cases of de novo DLBCL in the major pharmaceutical markets by molecular subtype: 2020-2030
            • Definition
            • Methods
            • Sources used for transformed incidence from FL to DLBCL
            • Number of diagnosed incident cases of transformed incidence from FL to DLBCL in the major pharmaceutical markets: 2020-2030
            • Definition
            • Methods
            • Sources used for transformed incidence from CLL to DLBCL
            • Number of diagnosed incident cases of transformed incidence from CLL to DLBCL in the major pharmaceutical markets: 2020-2030
            • FL patient flow
            • Number of drug-treatable cases of FL in the major pharmaceutical markets by line: 2020-2030
            • DLBCL drug-treatable population
            • DLBCL patient flow
            • Number of drug-treatable cases of DLBCL in the major pharmaceutical markets by line: 2020-2030
            • MCL drug-treatable population
            • MCL patient flow
            • Number of drug-treatable cases of MCL in the major pharmaceutical markets by line: 2020-2030
            • CLL / SLL drug-treatable population
            • CLL / SLL patient flow
            • Number of drug-treatable cases of CLL / SLL in the major pharmaceutical markets by line: 2020-2030
            • Number of drug-treated cases of FL in the major pharmaceutical markets by line: 2020-2030
            • Number of drug-treated cases of DLBCL in the major pharmaceutical markets by line: 2020-2030
            • Number of drug-treated cases of MCL in the major pharmaceutical markets by line: 2020-2030
            • Number of drug-treated cases of CLL / SLL in the major pharmaceutical markets by line: 2020-2030
        • Current treatment
          • Key findings
            • Treatment goals
              • Key endpoints used in clinical trials for NHL
            • Key current therapies
              • Overview
              • Mechanism of action of key current drug classes used for NHL
              • Current treatments used for NHL
              • Market events impacting the use of key current therapies in NHL
              • Advantages and disadvantages of rituximab (Rituxan / MabThera)
              • Ongoing clinical development of rituximab (Rituxan / MabThera)
              • Key ongoing clinical trials of rituximab (Rituxan / MabThera) in the treatment of NHL
              • Expert insight: rituximab (Rituxan / MabThera)
              • Advantages and disadvantages of Gazyva / Gazyvaro
              • Key results from select clinical trials investigating Gazyva / Gazyvaro for the treatment of NHL
              • Ongoing clinical development of Gazyva / Gazyvaro
              • Key ongoing clinical trials of Gazyva / Gazyvaro in the treatment of NHL
              • Expert insight: Gazyva / Gazyvaro
              • Key results from select clinical trials investigating Monjuvi / Minjuvi for the treatment of NHL
              • Ongoing clinical development of Monjuvi / Minjuvi
              • Key ongoing clinical trials of Monjuvi / Minjuvi in the treatment of NHL
              • Expert insight: Monjuvi / Minjuvi
              • Advantages and disadvantages of Arzerra
              • Clinical development of Arzerra
              • Expert insight: Arzerra
              • Advantages and disadvantages of Campath / MabCampath
              • Advantages and disadvantages of Polivy
              • Key results from select clinical trials investigating Polivy for the treatment of NHL
              • Analysis of the clinical development program for Polivy
              • Key ongoing clinical trials of Polivy in the treatment of NHL
              • Expert insight: Polivy
              • Key results from select clinical trials investigating Zynlonta for the treatment of NHL
              • Ongoing clinical development of Zynlonta
              • Key ongoing clinical trials of Zynlonta in the treatment of NHL
              • Expert insight: Zynlonta
              • Advantages and disadvantages of Venclexta / Venclyxto
              • Key results from select clinical trials investigating Venclexta / Venclyxto for the treatment of NHL
              • Ongoing clinical development of Venclexta / Venclyxto
              • Key ongoing clinical trials of Venclexta / Venclyxto in the treatment of NHL
              • Expert insight: Venclexta / Venclyxto
              • Advantages and disadvantages of lenalidomide (Revlimid)
              • Key results from select clinical trials investigating lenalidomide (Revlimid) for the treatment of NHL
              • Ongoing clinical development of lenalidomide (Revlimid)
              • Key ongoing phase III clinical trials of lenalidomide (Revlimid) in the treatment of NHL
              • Advantages and disadvantages of bortezomib (Velcade)
              • Expert insight: bortezomib (Velcade)
              • Advantages and disadvantages of Temsirolimus (Torisel)
              • Advantages and disadvantages of Imbruvica
              • Key results from select clinical trials investigating Imbruvica for the treatment of NHL
              • Ongoing clinical development of Imbruvica
              • Key ongoing Phase III clinical trials of Imbruvica in the treatment of NHL
              • Expert insight: Imbruvica
              • Advantages and disadvantages of Calquence
              • Key results from select clinical trials investigating Calquence for the treatment of NHL
              • Ongoing clinical development of Calquence
              • Key ongoing clinical trials of Calquence in the treatment of NHL
              • Expert insight: Calquence
              • Key results from select clinical trials investigating Brukinsa for the treatment of NHL
              • Ongoing clinical development of Brukinsa
              • Key ongoing clinical trials of Brukinsa in the treatment of NHL
              • Expert insight: Brukinsa
              • Advantages and disadvantages of Zydelig
              • Key results from select clinical trials investigating Zydelig for the treatment of NHL
              • Ongoing clinical development of Zydelig
              • Key ongoing clinical trials of Zydelig in the treatment of NHL
              • Expert insight: Zydelig
              • Advantages and disadvantages of Aliqopa
              • Key results from select clinical trials investigating Aliqopa for the treatment of NHL
              • Ongoing clinical development of Aliqopa
              • Key ongoing clinical trials of Aliqopa in the treatment of NHL
              • Expert insight: Aliqopa
              • Advantages and disadvantages of Copiktra
              • Key results from select clinical trials investigating Copiktra for the treatment of NHL
              • Ongoing clinical development of Copiktra
              • Key ongoing clinical trials of Copiktra in the treatment of NHL
              • Expert insight: Copiktra
              • Key results from select clinical trials investigating Ukoniq for the treatment of NHL
              • Ongoing clinical development of Ukoniq
              • Key ongoing clinical trials of Ukoniq in the treatment of NHL
              • Expert insight: Ukoniq
              • Advantages and disadvantages of Bendamustine
              • Expert insight: Bendamustine
              • Advantages and Disadvantages of Pixuvri
              • Clinical development of Pixuvri
              • Advantages and disadvantages of Yescarta
              • Key results from select clinical trials investigating Yescarta for the treatment of NHL
              • Ongoing clinical development of Yescarta
              • Key ongoing clinical trials of Yescarta in the treatment of NHL
              • Expert insight: Yescarta
              • Advantages and disadvantages of Kymriah
              • Key results from select clinical trials investigating Kymriah for the treatment of NHL
              • Ongoing clinical development of Kymriah
              • Key ongoing clinical trials of Kymriah in the treatment of NHL
              • Expert insight: Kymriah
              • Tecartus
              • Key results from select clinical trials investigating Tecartus for the treatment of NHL
              • Ongoing clinical development of Tecartus
              • Key ongoing clinical trials of Tecartus in the treatment of NHL
              • Expert insight: Tecartus
              • Key results from select clinical trials investigating Breyanzi for the treatment of NHL
              • Ongoing clinical development of Breyanzi
              • Key ongoing clinical trials of Breyanzi in the treatment of NHL
              • Expert insight: Breyanzi
              • Advantages and disadvantages of Keytruda
              • Key results from select clinical trials investigating Keytruda for the treatment of NHL
              • Ongoing clinical development of Keytruda
              • Key ongoing clinical trials of Keytruda in the treatment of NHL
              • Expert insight: Keytruda
              • Tazverik
              • Key results from select clinical trials investigating Tazverik for the treatment of NHL
              • Ongoing clinical development of Tazverik
              • Key ongoing clinical trials of Tazverik in the treatment of NHL
              • Expert insight: Tazverik
              • Key results from select clinical trials investigating Xpovio for the treatment of NHL
              • Ongoing clinical development of Xpovio / Nexpovio
              • Key ongoing clinical trials of Xpovio / Nexpovio in the treatment of NHL
              • Expert insight: Xpovio / Nexpovio
              • Key results from select clinical trials investigating Lunsumio for the treatment of NHL
              • Key ongoing clinical trials of Lunsumio in the treatment of NHL
              • Analysis of the clinical development program for Lunsumio
              • Expert insight: Lunsumio
            • Medical practice
              • First-line CLL / SLL drug-treatable population
              • First-line DLBCL drug-treatable population
              • First-line FL drug-treatable population
              • First-line MCL drug-treatable population
              • Relapsed / refractory CLL / SLL drug-treatable population
              • Relapsed / refractory DLBCL drug-treatable population
              • Relapsed / refractory FL drug-treatable population
              • Relapsed / refractory MCL drug-treatable population
              • Patient characteristics influencing drug selection in NHL
              • United States
              • Treatment decision tree for FL: United States
              • Treatment decision tree for CLL / SLL: United States
              • Treatment decision tree for DLBCL: United States
              • Treatment decision tree for MCL: United States
              • Treatment decision tree for FL: Europe
              • Treatment decision tree for CLL / SLL: Europe
              • Treatment decision tree for DLBCL: Europe
              • Treatment decision tree for MCL: Europe
              • Treatment decision tree for FL: Japan
              • Treatment decision tree for CLL / SLL: Japan
              • Treatment decision tree for DLBCL: Japan
              • Treatment decision tree for MCL: Japan
          • Unmet need overview
            • Current and future attainment of unmet needs in non-Hodgkin's lymphoma
            • Top unmet needs in non-Hodgkin's lymphoma: current and future attainment
            • Expert insight: unmet need in non-Hodgkin's lymphoma
          • Drug Pipeline
            • Pipeline
            • Regulatory Milestones
            • Indication Comparison
          • Emerging therapies
            • Key findings
              • Key emerging therapies
                • Notable developments among key emerging therapies for NHL
                • Key therapies in development for NHL
                • Estimated market authorization dates of key emerging therapies for the treatment of NHL
                • Key results from select clinical trials investigating Enzastaurin for the treatment of NHL
                • Key ongoing clinical trials of Enzastaurin in the treatment of NHL
                • Analysis of the clinical development program for Enzastaurin
                • Expert insight: Enzastaurin
                • Expectations for market authorization and sales opportunity of Enzastaurin in NHL
                • Key results from select clinical trials investigating ublituximab for the treatment of NHL
                • Key ongoing clinical trials of ublituximab in the treatment of NHL
                • Analysis of the clinical development program for ublituximab
                • Expert insight: ublituximab
                • Expectations for market authorization and sales opportunity of ublituximab in NHL
                • Key results from select clinical trials investigating glofitamab for the treatment of NHL
                • Key ongoing clinical trials of glofitamab in the treatment of NHL
                • Analysis of the clinical development program for glofitamab
                • Expert insight: Glofitamab
                • Expectations for market authorization and sales opportunity of glofitamab in NHL
                • Key results from select clinical trials investigating epcoritamab for the treatment of NHL
                • Key ongoing clinical trials of epcoritamab in the treatment of NHL
                • Analysis of the clinical development program for epcoritamab
                • Expert insight: Epcoritamab
                • Expectations for market authorization and sales opportunity of epcoritamab in NHL
                • Key results from select clinical trials investigating Adcetris for the treatment of NHL
                • Key ongoing clinical trials of Adcetris in the treatment of NHL
                • Analysis of the clinical development program for Adcetris
                • Expert insight: Adcetris
                • Expectations for market authorization and sales opportunity of Adcetris in NHL
                • Key ongoing clinical trials of zilovertamab vedotin in the treatment of NHL
                • Analysis of the clinical development program for zilovertamab vedotin
                • Key results from select clinical trials investigating zilovertamab vedotin for the treatment of NHL
                • Expectations for market authorization and sales opportunity of zilovertamab vedotin
                • Key results from select clinical trials investigating Opdivo for the treatment of NHL
                • Key ongoing clinical trials of Opdivo in the treatment of NHL
                • Analysis of the clinical development program for Opdivo
                • Expert insight: Opdivo
                • Expectations for market authorization and sales opportunity of Opdivo in NHL
                • Key results from select clinical trials investigating pirtobrutinib for the treatment of NHL
                • Key ongoing clinical trials of pirtobrutinib in the treatment of NHL
                • Analysis of the clinical development program for pirtobrutinib
                • Expert insight: Pirtobrutinib
                • Expectations for market authorization and sales opportunity of pirtobrutinib in NHL
                • Key results from select clinical trials investigating parsaclisib for the treatment of NHL
                • Key ongoing clinical trials of parsaclisib in the treatment of NHL
                • Analysis of the clinical development program for parsaclisib
                • Expert insight: parsaclisib
                • Expectations for market authorization and sales opportunity of parsaclisib in NHL
                • Zandelisib
                • Key results from select clinical trials investigating zandelisib for the treatment of NHL
                • Analysis of the clinical development program for zandelisib
                • Key ongoing clinical trials of zandelisib in the treatment of NHL
                • Expert insight: zandelisib
                • Expectations for market authorization and sales opportunity of zandelisib in NHL
                • Key results from select clinical trials investigating Onureg (oral azacitidine) for the treatment of NHL
                • Key ongoing clinical trials of Onureg (oral azacitidine) in the treatment of NHL
                • Analysis of the clinical development program for Onureg (oral azacitidine)
                • Expert insight: Onureg (oral azacitidine)
                • Expectations for market authorization and sales opportunity of Onureg (oral azacitidine) in NHL
              • Early-phase pipeline analysis
                • Select compounds in early-phase development for NHL
            • Access & reimbursement overview
              • Region-specific reimbursement practices
                • Key market access considerations in NHL: United States
                • General reimbursement environment: United States
                • Key market access considerations in NHL: EU5
                • General reimbursement environment: EU5
                • Key market access considerations in NHL: Japan
                • General reimbursement environment: Japan
            • Appendix
              • Non-Hodgkin's lymphoma bibliography

          Login to access report

          launch Related Market Assessment Reports